Citations

Clear

479 citation(s) found for "Tobias, JS".

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer
Walsh, Naomi , Hyland, Paula L. , Yang, Qi , Childs, Erica J., Collins, Irene , Wang, Zhaoming , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Gallinger, Steven , Goodman, Gary E. , Goodman, Phyllis J. , Hung, Rayjean J, Kurtz, Robert C. , Scélo, Ghislaine , Shu, Xiao Ou , Visvanathan, Kala , consortia, PanScan and PanC4, Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Borgida, Ayelet , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Chaffee, Kari G. , Foretová, Lenka , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward, Hackert, Thilo , Haiman, Christopher A. , Hartge, Patricia, Hasan, Manal , Helzlsouer, Kathy J., Herman, Joseph M. , Holly, Elizabeth A., Hoover, Robert N. , Hung, Rayjean J, Janout, Vladimí­r , Klein, Eric A. , Laheru, Daniel A. , Lee, I‐Min , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Porta, Miquel , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Strobel, Oliver , Thornquist, Mark, Wactawski‐Wende, Jean , Wareham, Nick, Weiderpass, Elisabete , Wentzensen, Nicolas , Wheeler, William, Zeleniuch‐Jacquotte, Anne , Kraft, Peter , Li, Donghui , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Rabe, Kari G. , Hung, Rayjean J. , Cleary, Sean, Weiderpass, Elisabete , Arslan, Alan A , Canzian, Federico , Hung, Rayjean J , Wactawski-Wende, Jean , Wang, Zhaoming , Visvanathan, Kala , Klein, Eric A , Strobel, Oliver , Kraft, Peter , Porta, Miquel , Real, Francisco X , Zeleniuch-Jacquotte, Anne , Zhang, Han , Mocci, Evelina , Zhang, Mingfeng , Freeman, Laura E. Beane , Duell, Eric J. , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J, Kooperberg, Charles , Malats, Núria , Marchand, Loı̈c Le , Neale, Rachel Ε. , Olson, Sara H. , Van Den Eeden, Stephen K , White, Emily , Zheng, Wei , consortia, PanScan and PanC4, Albanes, Demetrius , Bamlet, William R. , Boutron‐Ruault, Marie‐Christine , Brais, Lauren K , Chanock, Stephen Jacob , Cleary, Sean P. , Cotterchio, Michelle , Holcátová, Ivana , Hung, Rayjean J, Lu, Lingeng , Männistö, Satu , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Severi, Gianluca , Silverman, Debra T. , Sund, Malin , Tobias, Geoffrey S. , Wareham, Nick, Yu, Kai , Risch, Harvey A. , Ámundadóttir, Laufey T. , Yu, Kai , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 15, 2018 | Volume: 111 | Issue: 6 | Pages: 557-567

10.1093/jnci/djy155 | PMID 30541042 Get It

Neuroimaging of Early Life Epilepsy
Coryell, Jason , Gaillard, William D. , Shellhaas, Renée A. , Wusthoff, Courtney J. , Keator, Cynthia, Sullivan, Joseph , Loddenkemper, Tobias , Chu, Catherine J. , Massey, Shavonne L. , Saneto, Russel P., Berg, Anne T. , Wirrell, Elaine C., Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Berg, Anne T , Chu, Catherine J , Coryell, Jason , Wusthoff, Courtney J , Grinspan, Zachary M. , Wirrell, Elaine , Knupp, Kelly G. , Patel, Anup D. , Novotny, Edward J.

Mayo Clinic

Pediatrics | August 8, 2018 | Volume: 142 | Issue: 3 | Pages: No page available

10.1542/peds.2018-0672 | PMID 30089657 Get It

OBJECTIVES: We assessed the adherence to neuroimaging guidelines and the diagnostically relevant yield of neuroimaging in newly presenting early life epilepsy (ELE). METHODS: There were 775 children with a new diagnosis of epilepsy (<3 years old at onset) who were recruited through the ELE study at 17 US pediatric epilepsy centers (2012–2015) and managed prospectively for 1 year. The data were analyzed to assess the proportion of children who underwent neuroimaging, the type of neuroimaging, and abnormalities. RESULTS: Of 725 children (93.5%) with neuroimaging, 714 had an MRI (87% with seizure protocols) and 11 had computed tomography or ultrasound only. Etiologically relevant abnormalities were present in 290 individuals (40%) and included: an acquired injury in 97 (13.4%), malformations of cortical development in 56 (7.7%), and other diffuse disorders of brain development in 51 (7.0%). Neuroimaging was abnormal in 160 of 262 (61%) children with abnormal development at diagnosis versus 113 of 463 (24%) children with typical development. Neuroimaging abnormalities were most common in association with focal seizure semiology (40%), spasms (47%), or unclear semiology (42%). In children without spasms or focal semiology with typical development, 29 of 185 (16%) had imaging abnormalities. Pathogenic genetic variants were identified in 53 of 121 (44%) children with abnormal neuroimaging in whom genetic testing was performed. CONCLUSIONS: Structural abnormalities occur commonly in ELE, and adherence to neuroimaging guidelines is high at US pediatric epilepsy centers. These data support the universal adoption of imaging guidelines because the yield is substantially high, even in the lowest risk group.
634 Convective Radiofrequency Thermal Therapy (Rezum®) Effectively Treats Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Regardless of Obesity While Preserving Erectile and Ejaculatory Function
Köhler, Tobias , McVary, Kevin T. , Helo, Sevann , Tadros, Nicholas N. , Gupta, Nikhil

Mayo Clinic

The Journal of Sexual Medicine | June 29, 2018 | Volume: 15 | Issue: Supplement_3 | Pages: S367-S368

10.1016/j.jsxm.2018.04.541 Get It

053 Emerging Complications after Ectopic Placement of Reservoirs During Inflatable Penile Prosthesis Surgery: a Multi-institutional Experience
Hernandez, J. Clavell, Ring, Joshua , Trost, Landon , Köhler, Tobias , Wang, Rebecca J.

Mayo Clinic

The Journal of Sexual Medicine | June 29, 2018 | Volume: 15 | Issue: Supplement_3 | Pages: S147-S147

10.1016/j.jsxm.2018.04.057 Get It

Assessment of Interstitial Lung Disease Using Lung Ultrasound Surface Wave Elastography
Clay, Ryan , Bartholmai, Brian J. , Zhou, Boran , Karwoski, Ronald A., Peikert, Tobias, Osborn, Thomas G. , Rajagopalan, Srinivasan, Kalra, Sanjay , Zhang, Xiaoming , Karwoski, Ronald, Zhang, Xiaoming , Bartholmai, Brian J

Mayo Clinic

Journal of Thoracic Imaging | June 5, 2018 | Volume: 34 | Issue: 5 | Pages: 313-319

10.1097/rti.0000000000000334 | PMID 29877916 Get It

Purpose: Optimal strategies to detect early interstitial lung disease (ILD) are unknown. ILD is frequently subpleural in distribution and affects lung elasticity. Lung ultrasound surface wave elastography (LUSWE) is a noninvasive method of quantifying superficial lung tissue elastic properties. In LUWSE a handheld device applied at the intercostal space vibrates the chest at a set frequency, and the lung surface wave velocity is measured by an ultrasound probe 5 mm away in the same intercostal space. We explored LUWSE’s ability to detect ILD and correlated LUSWE velocity with physiological, quantitative, and visual radiologic features of subjects with known ILD and of healthy controls. Materials and Methods: Seventy-seven subjects with ILD, mostly caused by connective tissue disease, and 19 healthy controls were recruited. LUSWE was performed on all subjects in 3 intercostal lung regions bilaterally. Comparison of LUSWE velocities pulmonary function testing, visual assessment, and quantitative analysis of recent computed tomographic imaging with Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) software. Results: Sonographic velocities were higher in all lung regions for cases, with the greatest difference in the lateral lower lung. Median velocity in m/s was 5.84 versus 4.11 and 5.96 versus 4.27 (P<0.00001) for cases versus controls, left and right lateral lower lung zones, respectively. LUSWE velocity correlated negatively with vital capacity and positively with radiologist and CALIPER-detected interstitial abnormalities. Conclusions: LUSWE is a safe and noninvasive technique that shows high sensitivity to detect ILD and correlated with clinical, physiological, radiologic, and quantitative assessments of ILD. Prospective study in detecting ILD is indicated.
Modified Glanulopexy Technique for Supersonic Transporter Deformity and Glanular Hypermobility in Men With Penile Prostheses
Ziegelmann, Matthew , Alom, Manaf, Bole, Raevti , Köhler, Tobias , Trost, Landon , Ziegelmann, Matthew J

Mayo Clinic

The Journal of Sexual Medicine | May 3, 2018 | Volume: 15 | Issue: 6 | Pages: 914-919

10.1016/j.jsxm.2018.04.633 | PMID 29731427 Get It

Abstract Background Glanular hypermobility (GH) or supersonic transporter (SST) deformity are occasionally encountered during penile prosthesis (PP) implantation, yet management strategies are underreported with minimal data available on surgical outcomes. Aim To describe a modified technique for glanulopexy to correct GH/SST in men undergoing PP placement and assess outcomes associated with this technique. Methods Glanulopexy was performed in men with GH/SST identified at the time of or following PP placement. A modification to previously described techniques was performed, whereby a suture is passed into the glans and secured to the tissue overlying the corpora through small incisions on the lateral aspects of the distal penile shaft. Outcomes Correction of the anatomic deformity (GH/SST), device infection, and changes in penile sensation were evaluated during post-operative follow-up. Results From 2014–2017, a total of 12 patients underwent modified glanulopexy for GH/SST. Nine (75%) were performed at the time of PP, while the remaining 3 were performed in a delayed fashion. At a median follow-up of 12 months (range 1–33 months), all patients with the device in situ demonstrated appropriate glanular positioning, and no patients reported changes in penile sensation. A single patient required device removal secondary to infection. Clinical Translation Glanulopexy with permanent suture successfully corrects severe GH or SST in men with inflatable PP without reduced penile sensation. Conclusions Strengths of the current study include the description of a simple, safe, and reproducible technique for GH/SST that adds minimal operative time and can be performed under local anesthesia when necessary. To our knowledge, this represents one of the largest reported series of glanulopexy outcomes reported in the literature. Limitations include that this is a single-surgeon series, there is limited follow-up, and lack of a comparison group. Further study with external validation is warranted to establish the optimal role for the procedure.
Andrianne Mini-Jupette Graft at the Time of Inflatable Penile Prosthesis Placement for the Management of Post-Prostatectomy Climacturia and Minimal Urinary Incontinence
Yafi, Faysal A. , Andrianne, Robert, Alzweri, Laith , Brady, Jeffrey D., Butcher, Michael, Chevalier, Daniel, DeLay, Kenneth J., Faix, A. , Hatzichristodoulou, Georgios , Hellstrom, Wayne J.G. , Jenkins, Lawrence C. , Köhler, Tobias , Osmonov, Daniar , Park, Sun Hung, Schwabb, M. David, Valenzuela, Robert , Wilson, Steven K. , Renterghem, Koenraad van , Jenkins, Lawrence

Mayo Clinic

The Journal of Sexual Medicine | March 6, 2018 | Volume: 15 | Issue: 5 | Pages: 789-796

10.1016/j.jsxm.2018.01.015 | PMID 29523479 Get It

Abstract Background After radical prostatectomy (RP), erectile dysfunction, often necessitating the need for inflatable penile prosthesis (IPP) insertion, and urinary incontinence and climacturia can ensue. Aim To assess the efficacy and safety of the mini-jupette, a mesh used to approximate the medial aspects of the 2 corporotomies at the time of IPP insertion, for the management of climacturia and urine leakage in patients with minimal incontinence. Methods We conducted a pilot multicenter study of patients with post-RP erectile dysfunction and climacturia and/or mild urinary incontinence (≤2 pads/day [ppd]) undergoing IPP insertion with concomitant placement of a mini-jupette graft. Outcomes Pre- and postoperative erectile function, continence and climacturia, and overall surgical outcomes were assessed. Results 38 patients underwent the mini-jupette procedure. The mean age of the population was 65.3 years (SD = 7.7). 30 had post-RP climacturia and 32 patients had post-RP incontinence (mean = 1.3 ppd, SD = 0.8). 31 patients received Coloplast Titan, 4 received AMS 700 LGX, and 3 received AMS 700 CX IPPs. Mean corporotomy size was 2.9 cm (SD = 1.0). Mean graft measurements were 3.2 cm (SD = 0.9) for width, 3.3 cm (SD = 1.3) for length, and 11.0 cm2 (SD = 5.1) for surface area. At a mean follow-up of 5.1 months (SD = 6.9), there were 5 postoperative complications (13.2%) of which 4 required explantation. Climacturia and incontinence were subjectively improved in 92.8% and 85.7%, respectively. Mean ppd decreased by 1.3 postoperatively. Clinical Implications The Andrianne mini-jupette is a feasible adjunct to IPP placement that can be used for subsets of patients with post-RP climacturia and/or minimal incontinence. Strengths and Limitations Strengths of this study include the novel nature of this intervention, the multi-institutional nature of the study, and the promising results demonstrated. Limitations include the retrospective nature of the study and the heterogeneity of the techniques and grafts used by different surgeons involved. Conclusion Longer follow-up and larger patient cohorts are needed to confirm the long-term safety and benefits of this intervention.
Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance
Federer‐Gsponer, Joël R. , Quintavalle, Cristina , Müller, David C. , Dietsche, Tanja, Perrina, Valeria, Lorber, Thomas , Juškevičius, Darius , Lenkiewicz, E., Zellweger, Tobias, Barrett, Michael T. , Rentsch, Cyrill A. , Bubendorf, Lukas , Lenkiewicz, Elisabeth, Gasser, Thomas , Ruiz, Christian Felipe , Bubendorf, Lukas

Mayo Clinic

The Journal of Pathology | February 27, 2018 | Volume: 245 | Issue: 1 | Pages: 74-84

10.1002/path.5052 | PMID 29484655 Get It

AbstractUnderstanding the evolutionary mechanisms and genomic events leading to castration‐resistant (CR) prostate cancer (PC) is key to improve the outcome of this otherwise deadly disease. Here, we delineated the tumour history of seven patients progressing to castration resistance by analysing matched prostate cancer tissues before and after castration. We performed genomic profiling of DNA content‐based flow‐sorted populations in order to define the different evolutionary patterns. In one patient, we discovered that a catastrophic genomic event, known as chromothripsis, resulted in multiple CRPC tumour populations with distinct, potentially advantageous copy number aberrations, including an amplification of FK506 binding protein 4 (FKBP4, also known as FKBP52), a protein enhancing the transcriptional activity of androgen receptor signalling. Analysis of FKBP4 protein expression in more than 500 prostate cancer samples revealed increased expression in CRPC in comparison to hormone‐naïve (HN) PC. Moreover, elevated FKBP4 expression was associated with poor survival of patients with HNPC. We propose FKBP4 amplification and overexpression as a selective advantage in the process of tumour evolution and as a potential mechanism associated with the development of CRPC. Furthermore, FKBP4 interaction with androgen receptor may provide a potential therapeutic target in PC. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer
Lei, JT, Shao, Jieya , Zhang, J, Iglesia, Michael D. , Cao, Jin , Haricharan, Svasti , Kavuri, SM, Matsunuma, Ryoichi , Schmidt, Cecilia, Kosaka, Yoshimasa , Crowder, RJ, Hoog, J, Phommaly, Chanpheng, Gonçalves, Rodrigo , Ramalho, Susana , Rodrigues-Peres, RM, Lai, W-C, Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Davies, S. J. , Ma, C, Suman, VJ, Watson, Mark , Hoadley, KA, Thompson, Andrew , Perou, CM, Creighton, CJ, Ellis, MJ, Chan, David W. , Anurag, Meenakshi , Singh, Pankaj Kumar , Hampton, Oliver , Ma, C, Hunt, Kelly K. , Watson, M, Hoadley, Katherine A. , Maher, Christopher G.

Mayo Clinic

Cancer Research | February 15, 2018 | Volume: 78 | Issue: 4_Supplement | Pages: PD8-03-PD8-03

10.1158/1538-7445.sabcs17-pd8-03 Get It

Abstract Background. Dysregulation of the estrogen receptor gene (ESR1) is an established mechanism of inducing endocrine therapy resistance. We previously discovered a chromosomal translocation event generating an estrogen receptor gene fused in-frame to C-terminal sequences of YAP1 (ESR1-YAP1) that contributed to endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer models. This study compares functional, transcriptional, and pharmacological properties of additional ESR1 gene fusion events of both early stage (ESR1-NOP2) late stage (ESR1-YAP1 and ESR1-PCDH11x) breast cancers to gain a better understanding of therapeutic resistance and metastasis. Understanding the role of ESR1 fusions in inducing metastasis is critical, since the primary cause of death in breast cancer patients is through metastasis to distant sites. Methods. RNA-seq screens identified ESR1 fusions from early and late stage, endocrine therapy resistant breast tumor samples. Functional experiments were conducted using ER+ breast cancer cell lines, xenograft, and PDX models to test the ability of ESR1 fusions to induce therapeutic resistance and metastasis. ChIP-seq and RNA-seq were performed to examine transcriptional properties and differential gene expression induced by the fusions which directed subsequent pharmacological experiments with a CDK4/6 inhibitor. Results. ESR1-YAP1 and ESR1-PCDH11x promoted estrogen-independent and fulvestrant-resistant growth in vitro and induced greater tumor growth and increased metastatic capacity to the lungs of xenografted mice. In contrast, the ESR1-NOP2 fusion was sensitive to low estrogen conditions in vitro, and did not promote tumor growth. RNA-seq profiling revealed E2F targets pathway as the most highly enriched pathway induced by the ESR1 fusions. IHC revealed higher levels of pRb in ESR1-YAP1 and ESR1-PCDH11x xenograft tumors and subsequent CDK4/6 inhibition completely blocked tumor growth in an ESR1-YAP1 PDX model. Integrating RNA-seq with ChIP-seq data, we discovered a set of EMT and metastasis genes bound by all ESR1 fusions and WT-ER, but whose expression was strongly and uniquely up-regulated only by the ESR1-YAP1 and ESR1-PCDH11x fusions. These studies also revealed gained sites bound only by the ESR1-YAP1 and ESR1-PCDH11x fusions, not bound by WT-ER nor ESR1-NOP2. Genes mapping to these sites have a role in metastatic biology and were highly up-regulated by the YAP1 and PCDH11x fusions, potentially mediated by long range transcriptional activation. Conclusion. ESR1-YAP1 and ESR1-PCDH11x are driver fusions that occur in drug-resistant, advanced stage breast cancer and are a new class of recurrent somatic mutation that can cause acquired endocrine therapy resistance, yet can be treated with CDK4/6 inhibition. These driver fusions also confer increased metastatic ability through their ability to drive expression of genes that contribute to EMT and metastasis. In contrast, ESR1-NOP2 did not produce functional protein and appears to be a passenger event. These studies may provide pre-clinical rationale for targeting ESR1 translocated breast tumors, since the presence of an ESR1 driver fusion places a patient in a therapeutic category where none of the currently available endocrine therapies are likely to be effective. Citation Format: Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, Haricharan S, Kavuri SM, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Rodrigues-Peres RM, Lai W-C, Hampton O, Rogers A, Tobias E, Parikh P, Davies S, Ma C, Suman V, Hunt K, Watson M, Hoadley KA, Thompson A, Perou CM, Creighton CJ, Maher C, Ellis MJ. ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD8-03.